TACR1 and glioma: Moreover, SP analogue antagonists (synonymous of NK-1 receptor antagonists) inhibited, both in vitro and in vivo, the growth of small cell lung cancer [3], as well as it is known that other NK-1 receptor antagonists inhibited in vivo the growth of glioma and breast carcinoma cells [30,31].